# Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer

> **NCT04984096** · — · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04984096
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984096, "Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04984096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*